Trials / Recruiting
RecruitingNCT06856343
REBECCA Real-world Early BrEast CanCer mAnagement
REBECCA Real-world Early BrEast CanCer mAnagement REBECCA. a French National Multicentric Real-world Study of Early Breast Cancer Patients
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 126 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
Detailed description
The purpose to this observational study is to evaluate the rate of completion of adjuvant Olaparib treatment for HER2-negative early breast cancer patients in France.
Conditions
Timeline
- Start date
- 2024-12-30
- Primary completion
- 2028-01-31
- Completion
- 2028-01-31
- First posted
- 2025-03-04
- Last updated
- 2026-03-25
Locations
58 sites across 1 country: France
Source: ClinicalTrials.gov record NCT06856343. Inclusion in this directory is not an endorsement.